BGMA Chief Samuels Sees Boost From UK Biosimilars Pathway
Also Sets Out Aspirations For Repurposing Project And COVID Expectations
In the second part of an exclusive interview with Generics Bulletin, BGMA chief executive Mark Samuels talks about the UK’s new biosimilars licensing pathway, future trade deals and IP, and efforts around repurposing generics, as well as looking ahead to how the UK’s vaccination program could reshape the COVID-19 pandemic.
